Relief Therapeutics Holding AG reports positive results from pivotal bioequivalence study of RLF‑OD032

Relief Therapeutics Holding AG (SWX:RLF) announced on 29 October 2025 that the pivotal bioequivalence study of its candidate RLF‑OD032 has produced positive results. The announcement was issued pursuant to Article 53 of the Swiss Code of Obligations and was released as an ad‑hoc announcement via the company’s regulatory filing.

Study outcome

The study evaluated the bioequivalence of RLF‑OD032, a drug candidate intended for the treatment of rare metabolic disorders. The results met all primary efficacy and safety endpoints defined in the study protocol. According to the company, the data support the drug’s potential to meet regulatory requirements for approval in the target markets.

Market reaction

At the close of the Swiss market on 29 October 2025, Relief Therapeutics’ share price was CHF 3.145. This represents a decline from the CHF 5.70 closing level observed one year earlier on 29 October 2024, when the share traded at that time. The price movement reflects the market’s adjustment to the company’s recent disclosures and the broader context of the Swiss market index (SPI) activity.

The SPI itself moved modestly on 29 October 2025, closing at 17 047,45 points, a decline of 0,19 percent relative to the previous session. The index’s performance indicates a generally subdued trading environment in Zürich, which may have influenced investor sentiment toward Relief Therapeutics.

Company context

Relief Therapeutics is a commercial‑stage biopharmaceutical company headquartered in Geneva, Switzerland. It focuses on developing therapies for rare metabolic disorders, rare pulmonary diseases, and rare connective tissue disorders. The company’s market capitalization stands at approximately 39 million CHF, and its price‑to‑earnings ratio is currently negative, at –2,29, reflecting its ongoing investment in research and development.

Summary

Relief Therapeutics Holding AG has reported that the pivotal bioequivalence study for RLF‑OD032 has achieved positive results, supporting the compound’s potential regulatory progress. The company’s share price closed at CHF 3.145 on 29 October 2025, following a year‑long decline from CHF 5.70. The broader Swiss market index (SPI) recorded a modest decline that day, indicating a cautious trading atmosphere.